Biotechnology

Fiera MoistureWiser Reviews: Don't Buy Till You’ve Read This!

December 30, 2025 12:40 AM

Aging skin affects millions of women worldwide, bringing visible changes that can make daily self-care feel more frustrating than empowering. Over time, natural collagen levels decline, moisture retention weakens, and skin that once felt smooth and resilient may begin to appear dry, dull, and less firm. For many women, especially those over 40, this shift makes maintaining healthy, radiant skin more challenging, even with consistent skincare...

Read more

PetVivo Holdings, Inc. Presenting at the 3rd Annual DealFlow Discovery Conference

December 23, 2025 8:00 AM

PetVivo Holdings, Inc. (OTCQX:PETV)(OTCID:PETVW), in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026. John Lai, Chief Executive Officer of PetVivo Holdings, Inc., will deliver a company...

Read more

Nature Cell Announces Revival of Vascostem's U.S. FDA Clinical Development for Critical Limb Ischemia Treatment

December 23, 2025 8:00 AM

Nature Cell Co., Ltd., a biotechnology company focused on adult stem cell therapies (Chairman: Jeong-Chan Ra), announced the full-scale advancement of its stem cell therapy Vascostem for the treatment of Critical Limb Ischemia (CLI) patients in the United States. The company aims to accelerate clinical development through the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation. Development activities in the U.S. will be led by its...

Read more

Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer

December 22, 2025 2:16 AM

Faron Pharmaceuticals Ltd. (AIM:ARN, First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company, today announces the finalization of agreements to initiate the BLAZE trial, a new investigator-initiated trial (IIT) in the UK. The trial is conducted via a strategic collaboration with The Institute of Cancer Research, London (ICR), operating in partnership with The Royal Marsden NHS Foundation Trust. This collaboration...

Read more

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

December 19, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today announced that the United States Patent and Trademark Office (USPTO) has officially issued U.S. Patent No. 12,491,200, covering the Company's novel microdose-based cannabinoid treatment of stuttering (stammering) and Tourette's Syndrome. The...

Read more

Alligator Bioscience Announces Preliminary Outcome in Rights Issue

December 19, 2025 6:45 AM

Alligator Bioscience (STO:ATORX) - The Board of Directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company"), today announces the preliminary outcome of the rights issue of units that was announced on 22 October 2025 (the "Rights Issue"). The preliminary outcome indicates that the Rights Issue has been subscribed to approximately 64.8 percent with and without exercise of unit rights, of which approximately 61.2 percent were...

Read more

Vicore Pharma To Move To The Nasdaq Stockholm Mid Cap Segment

December 19, 2025 2:15 AM

Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs) today announced that Nasdaq has completed its annual review of its Nordic market capitalization (market cap) segments and will move Vicore Pharma from the Small Cap segment to the Mid Cap segment effective January 2, 2026. Link to press release from Nasdaq. For further information, please contact: Megan...

Read more

LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor

December 18, 2025 6:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that Dr. Peter Singer, a global health expert and former Special Advisor to the Director General of the World Health Organization (WHO), has joined the Company as a Scientific Advisor. Dr. Singer brings over 25 years of leadership in health innovation, public health policy, and global development. At WHO, he played a key role in...

Read more

Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC

December 18, 2025 8:35 AM

Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that the U.S. Patent and Trademark Office has issued the Company a patent titled "Organic Solvent Free Compositions Compromising Protein-Polymer Conjugates and Uses Thereof" for its lead product, GerlinC®, addressing the liquid, ready to use version of the product, as well...

Read more

BioInvent to Participate in Upcoming Investor Conference

December 18, 2025 8:10 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that representatives from the Company management team will participate in the following upcoming investor conferences this January: J.P. Morgan 2026 Healthcare Conference, San Francisco, US Format: One-on-one meetings Date:...

Read more

Biovica International AB - Q2 Interim report Aug - Oct 2025

December 18, 2025 2:50 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Positioned for growth in Pharma Services and in the USA Q2 (August- October 2025) (comparison figures same period 2024) Net sales amounted to SEK 2,675 (2,312) thousand for the quarter, corresponding to an increase of 16%. In local currency, net sales increased by 27%. Cash flow from operating activities amounted to SEK -18,111 (- 21,053) thousand. At the end of the quarter, cash and...

Read more

Composition of Faron Pharmaceutical's Shareholders' Nomination Board

December 17, 2025 9:45 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the following members have been re-elected by a meeting of the Company's five largest shareholders to Faron Pharmaceuticals Ltd's Shareholders' Nomination Board: Timo Syrjälä, representing himself (Chair) Erkka Kohonen, representing Varma Mutual Pension...

Read more

Single Injection of JointStem Demonstrates Sustained Clinical Benefits Over Five Years

December 16, 2025 11:00 AM

Nature Cell Co., Ltd., a biopharmaceutical company specializing in adult stem cell-based therapies (Chairman: Jeong-Chan Ra), announced the results of a long-term follow-up study tracking patients for up to five years who participated in the Korean Phase 3 clinical trial of JointStem, an investigational stem cell therapy for severe knee osteoarthritis. This long-term follow-up study assessed long-term outcomes following a single intra-articular...

Read more

uBriGene Launches LVV Turbo(TM) - Its Next-Generation GMP Lentiviral Vector Manufacturing Platform - and announces a Strategic Partnership with Syenex for integration of its UltraCell(TM) Technology

December 16, 2025 7:30 AM

uBriGene Biosciences, a leading global lentivirus CDMO specializing in Advanced Therapy Medicinal Product (ATMP) GMP development and manufacturing, today announced the official rebranding of its GMP lentiviral vector manufacturing platform to LVV Turbo™, a high-performance system designed to deliver exceptional productivity, superior downstream yields, and a markedly lower cost of LVV manufacturing, enabling faster and more efficient vector...

Read more

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

December 15, 2025 9:00 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today commented on recent federal policy momentum surrounding the potential reclassification of cannabis to Schedule III and its implications for the regulated cannabinoid pharmaceutical sector. Recent reports indicating a possible shift in...

Read more

Biovica Signs Client Bill Agreement with Leading U.S. NCI-Designated Cancer Center

December 15, 2025 2:50 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announced that the company has entered into a commercial agreement (client bill agreement) with a leading U.S. NCI-designated Comprehensive Cancer Center. The agreement enables clinicians at the institution to order DiviTum® TKa, Biovica's FDA-cleared blood-based biomarker test, for clinical use in breast cancer. The agreement...

Read more

LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies

December 11, 2025 6:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") announces that it has filed a provisional patent application intended to cover a needle-free delivery platform for GLP/GIP[1]-based therapies used in obesity and metabolic disease. LIR filed the provisional patent application titled "Transdermal and Lingual Delivery System for GLP-1 Inhibitors" with the United States Patent and Trademark Office (USPTO). The...

Read more

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

December 11, 2025 5:00 PM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") was convened and adjourned without any business conducted due to lack of the required quorum. A quorum is necessary to hold the Annual Meeting. There were fewer than a...

Read more

eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion

December 11, 2025 4:10 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals and new medicines - announced the successful achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process using its proprietary exozyme-based, cell-free biomanufacturing platform. This effort, with a conversion level of over 99% from feedstock to product, marks a major...

Read more

Faron Issues Second Tranche of Bonds With an Aggregated Principal Amount of Eur 10 Million Under its Convertible Bond Arrangement

December 11, 2025 3:45 AM

Faron Pharmaceuticals Ltd. (AIM:FARN, First North:FARON, "Faron" or the "Company")(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announced on 3 April 2025 that the Company has entered into a subscription agreement (the "Subscription Agreement") with an entity managed by Heights Capital Management, Inc. ("HCM") regarding the issuance and subscription of amortising senior unsecured convertible...

Read more